DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine (penicillamine) Capsules, 250 mg, approved by the U.S. Food and Drug Administration (USFDA).

The Cuprimine brand and generic market had U.S. sales of approximately $80 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.Dr. Reddy’s Penicillamine Capsules, USP is available as 250 mg capsules in a bottle count sizes of 100.

Recently the company also announced the entry into the hospital nutrition segment with the launch of its nutrition drink, ‘Celevida Maxx’ in India. It is a unique addition to the Dr. Reddy’s nutrition portfolio and is designed to help manage the nutritional needs of Cancer, Critical Care and Chronic Obstructive Pulmonary Disease (COPD) patients in India.

M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s Laboratories said, “We are pleased to foray into the hospital nutrition segment in India. With Celevida Maxx, we look forward to strengthening our presence in the nutrition segment and continue making a
positive impact on patients’ lives.”

Dr. Reddy’s Celevida Maxx contains a unique triple action formula of high protein, high omega 3 fatty acids to help tackle the problem of inflammation and Astaxanthin, which is clinically proven to support immunity. A single serving of Celevida Maxx has been designed keeping patient compliance in mind. It offers high protein in a single serve of 33 gms, with medium chain triglycerides (MCT) that get easily absorbed in the body and readily provide energy. Malnourished patients need ready source of energy that can be easily absorbed with high protein thereby helping stabilize the rapid weight loss that is seen in conditions like cancer.
Celevida Maxx contains vegetarian ingredients, no added sugar and comes in two flavors, Orange and Strawberry.

Cancer is the second most common cause of death in India and the estimated number of people living with the disease is around 2.25 million. It is noted that, the prevalence of malnutrition in Cancer patients is as high as 80% and up to 78% in critical care patients. As a result, patients suffer further complications like fatigue, poor response to treatment and increased hospital stay which in turn further decreases the nutritional status of the patients. The recent guidelines on Medical Nutrition Therapy (MNT) highlights the importance of breaking the malnutrition cycle due to chronic diseases and its associated comorbidities. Thus, compliance with the right nutrition solution plays an equally important role to meet the
nutritional needs of patients.

In 2019, Dr. Reddy’s entered the nutritional market with Celevida, a clinically proven nutrition drink that
is designed for diabetes patients.